Landos Biopharma appoints Greg Oakes to its Board of Directors as CEO

– USA, VA –  Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company today announced the appointment of Greg Oakes to its Board of Directors as President and CEO, effective immediately, replacing interim CEO Tim Mayleben, who will continue to serve on the Board of Directors.

“We are thrilled to name Greg as President and CEO of Landos,” said Board Chairman, Chris Garabedian. “Greg is an industry veteran with a proven track record of developing and commercializing innovative products for multiple therapeutic areas and delivering value for shareholders and patients alike. We are excited to leverage Greg’s strong background in inflammation and immunology as we refine and finalize developments plans for our three clinical-stage product candidates.”

About Gregory Oakes

Greg Oakes is an accomplished pharmaceutical industry executive bringing more than 25 years of experience to Landos.

Mr. Oakes has more than 25 years of experience creating value for small, mid-sized, and large pharmaceutical companies. Before joining Landos, he served as President, North America, EVP, and member of the Executive Committee of Vifor Pharma since 2020. Previously, he served as Corporate VP and Global Integration Lead for Otezla® at Amgen from 2019 to 2020, overseeing the integration of the $2 billion brands acquired from Celgene, and positioning it for sustained growth. Mr. Oakes served as Corporate VP and US General Manager, U.S. Inflammation and Immunology, at Celgene from 2017 to 2019. While at Celgene, Mr. Oakes also helped steer the $74 billion acquisition by Bristol-Myers Squibb and the $13.4 billion divestiture of Otezla. Before Celgene, Mr. Oakes held several positions at Novartis, including Head of Sandoz Biopharmaceuticals, North America and SVP, Market Access, and Primary Care.

He began his career at Schering-Plough where he held executive roles both in the U.S. and Europe.

“I am honored to be joining Landos at such a pivotal time for the Company,” said Gregory Oakes. “With a promising pipeline of clinical-stage assets and a sharpened focus on pursuing the most promising target indications, Landos has a strong foundation in place. I believe that Landos has the potential to change the lives of patients suffering from autoimmune diseases, and I’m excited about the tremendous clinical and commercial opportunities ahead of us. I look forward to working with and growing Landos’ talented team to deliver on our mission of addressing the therapeutic gap for patients with autoimmune diseases.”

He currently sits on the Boards of BioNJ and Defender Pharmaceuticals. In addition, Mr. Oakes serves on Clemson University’s Department of Management Advisory Board at the Wilbur O. and Ann Powers College of Business. Mr. Oakes previously served on the Board of First Wave Biopharma, Inc. and United Way of Northern New Jersey, and also served on various Executive Committees at Celgene, Novartis, and Schering-Plough.

Mr. Oakes holds a bachelor’s degree in Marketing and Business Administration from Edinboro University and an M.B.A. from Clemson University.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. We believe we were the first to identify and target LANCL2, NLRX1, and PLXDC2, which are immunometabolic pathways or targets. Our core expertise is the discovery of novel pathways at the interface of immunity and metabolism. We leverage our proprietary advanced artificial intelligence-based integrated computational and experimental precision medicine platform, our LANCE platform, to identify novel therapeutic targets based on predictions of immunometabolic function. We then identify and create novel therapeutic candidates to engage those novel targets in areas of unmet medical need. We have identified seven novel immunometabolic pathways or targets. Our near-term focus is on our clinical-stage programs including omilancor for the treatment of UC, NX-13 for the treatment of UC, and LABP-104 for the potential treatment of SLE and/or RA.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team